| NCT02529995 | Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive | Drug: AZD9291 40 mg|Drug: AZD9291 80 mg | AstraZeneca | Phase 1 | 2015-08-01 | 2017-01-13 |
| NCT02197247 | Non Small Cell Lung Cancer | Procedure: Pharmacokinetic sampling - AZD9291|Drug: Rifampicin|Drug: AZD9291 tablet dosing|Procedure: Pharmacokinetic sampling - rifampicin|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550 | AstraZeneca | Phase 1 | 2014-12-01 | 2017-02-03 |
| NCT02161770 | Solid Tumours | Drug: AZD9291 tablet dosing|Procedure: Pharmacokinetic sampling - AZD9291|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550 | AstraZeneca | Phase 1 | 2014-12-22 | 2017-03-21 |
| NCT02163733 | Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer | Drug: AZD9291 tablets|Procedure: Pharmacokinetic sampling - AZD9291|Other: Dietary Fasted|Other: Dietary High Fat|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550 | AstraZeneca | Phase 1 | 2014-11-01 | 2017-02-03 |
| NCT02491944 | Oncology | Drug: AZD9291|Drug: [14C]AZD9291 | AstraZeneca | Phase 1 | 2015-07-01 | 2016-08-19 |
| NCT02224053 | Healthy Volunteer | Procedure: Pharmacokinetic sampling - AZD9291|Drug: AZD9291 tablet dosing|Drug: Omeprazole tablet dosing|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550 | AstraZeneca | Phase 1 | 2014-09-01 | 2016-05-23 |
| NCT02317016 | Non Small Cell Lung Cancer | Procedure: Pharmacokinetic sampling - AZD9291|Drug: AZD9291 tablet dosing|Drug: Rosuvastatin|Procedure: Pharmacokinetic sampling - rosuvastatin|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550 | AstraZeneca | Phase 1 | 2015-03-01 | 2017-02-03 |
| NCT02157883 | Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer | Procedure: Pharmacokinetic sampling|Drug: AZD9291|Drug: Itraconazole | AstraZeneca | Phase 1 | 2014-11-01 | 2017-01-09 |
| NCT02096679 | Healthy Volunteers | Drug: AZD9291 | AstraZeneca | Phase 1 | 2014-05-01 | 2015-10-01 |
| NCT02923947 | Solid Tumours | Drug: Osimertinib; AZD9291 | AstraZeneca|Quintiles, Inc. | Phase 1 | 2017-01-01 | 2016-10-03 |
| NCT02908750 | Non Small Cell Lung Cancer | Drug: Fexofenadine tablet dosing|Drug: Osimertininb tablet dosing | AstraZeneca|Quintiles, Inc. | Phase 1 | 2017-01-01 | 2016-09-23 |
| NCT02511106 | Stage IB-IIIA Non-small Cell Lung Carcinoma | Drug: AZD9291 80 mg/40 mg|Drug: Placebo AZD9291 80 mg/40 mg | AstraZeneca|Parexel | Phase 3 | 2015-10-01 | 2017-02-28 |
| NCT02296125 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer | Drug: AZD9291 80 mg/40 mg + placebo|Drug: Placebo Erlotinib 150/100mg|Drug: Placebo Gefitinib 250 mg|Drug: Erlotinib 150/100 mg|Drug: Gefitinib 250 mg|Drug: Placebo AZD9291 80 mg/ 40 mg | AstraZeneca|Parexel | Phase 3 | 2014-12-03 | 2017-03-20 |
